TAK: 武田制药

TAK新闻

• 12:38 Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
• 12:38 诺瓦瓦克斯第二大股东抛售3260万美元股票，结束激进施压
• 09:53 武田宣布来自 VERDICT 的新数据表明，使用静脉注射 ENTYVIO 治疗成人以实现无皮质类固醇疾病缓解，可显著延长首次溃疡性结肠炎相关并发症的发生时间，将 UC 并发症风险降低近 70%
• 09:53 Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC...
• 17:52 Ascentage Pharma Stock Could More Than Double: Analyst
• 07:01 此前报道：武田在日本和中国推出首创食欲素受体激动剂 ORZEYFUL，用于治疗1型发作性睡病；在 DEA 完成管制分类后，美国将于下月上市
• 07:01 Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
• 12:13 Takeda Reports TAK-881 Cuts Infusion Volume 50%, Single-Site Infusion Time 42.6% Vs. HyQvia In Phase 2/3 Immunodeficiency Trial
• 19:48 Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline
• 06:52 Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
• 06:52 武田公布3期数据：每日一次口服扎索替尼布在第16周实现PASI 100的比例为36.5%，高于德克拉维替尼的13.9%；实现PASI 90的比例为62.5%，高于34.0%；目前正接受FDA和EMA对斑块型银屑病的审评
• 13:17 KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
• 12:04 Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
• 12:04 Keros Therapeutics预计在ELRiSE MF临床试验首位患者给药后，依据其与武田的Elritercept许可协议将获得2000万美元的开发里程碑付款
• 18:30 This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO
• 19:17 Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
• 13:22 5 Undervalued Oncology Stocks Wall Street Is Overlooking (NASDAQ:IBB)
• 10:03 Best Value Stocks to Buy for September 14th
• 09:28 Best Income Stocks to Buy for September 14th
• 13:40 Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
• 13:16 Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data
• 18:57 Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
• 16:38 Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)
• 19:13 Silence Therapeutics: Making Some Recent Noise (NASDAQ:SLN)